Early anthracycline cardiotoxicity in adolescents and young adults with sarcoma: a prospective echocardiographic study
Open Access
- 5 May 2026
- journal article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (3)
Abstract
Background: Adolescents and young adults (AYAs) with sarcomas often receive high-dose doxorubicin (Dox), but data on early cardiotoxicity in this population are limited. Objectives: To prospectively evaluate early echocardiographic changes in AYAs with sarcoma treated with high-dose Dox. Methods: AYAs (15–39 years) with sarcoma treated at a tertiary cancer centre (2018–22) were prospectively enroled. Echocardiograms were performed at baseline, 1 and 2 years after cancer therapy initiation and interpreted by a single cardiologist. The primary endpoint was a >10% absolute reduction in left ventricular ejection fraction (LVEF), an absolute LVEF 10% decrease in LV wall thickness/dimension (LVWT/D) ratio from baseline. Secondary endpoints included longitudinal changes in cardiac structure, chamber volumes, systolic and diastolic function, and strain. Results: Of 70 patients, 56 completed at least two of three study echocardiograms (median age 22.6 [IQR, 17.6–30.5] years; 41% female, 84% white). Median cumulative Dox dose was 450 (IQR, 370–450) mg/m2; 75% received dexrazoxane. The primary endpoint was met by 44.4% at 1 year and 27.5% at 2 years, driven primarily by LVWT/D ratio decline (37% at 1 year, 25% at 2 years), while significant LVEF decline was observed in 11.1% and 2.5%, respectively. Significant absolute changes at 1 year included LVEF (−2.73 ± 4.3%, P < .001), global longitudinal strain magnitude (−1.37 ± 2.56%, P = .002), septal e′ (−1.75 ± 2.48 cm/s, P < .001), and lateral e′ (−2.78 ± 3.44 cm/s, P < .001), persisting at 2 years. One patient (1.8%) developed ventricular fibrillation and heart failure with reduced ejection fraction, with LVEF recovery within 1 year. Conclusions: Over one-third of AYAs with sarcoma met the primary endpoint at 1 year, with half of these abnormalities persisting at 2 years, primarily driven by LVWT/D ratio reductions. Subclinical changes in strain and diastolic function were observed, reflecting the broad cardiac impact of high-dose Dox in this population.Keywords
Funding Information
- Cancer Prevention and Research Institute of Texas (RP200381)
- National Cancer Institute (P30 CA016672)
This publication has 20 references indexed in Scilit:
- Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of EchocardiographyJournal of the American Society of Echocardiography, 2019
- Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2017
- Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic TherapyAnnals of Internal Medicine, 2016
- Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure TherapyCirculation, 2015
- Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood CancerJACC, 2015
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2015
- Quality Control and Reproducibility in M‐Mode, Two‐Dimensional, and Speckle Tracking Echocardiography Acquisition and Analysis: The CARDIA Study, Year 25 Examination ExperienceEchocardiography, 2014
- Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialThe Lancet Oncology, 2010
- Recommendations for the Evaluation of Left Ventricular Diastolic Function by EchocardiographyEuropean Heart Journal - Cardiovascular Imaging, 2008
- Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2005